Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bioconnect Systems Inc.

www.bioconnectsystems.com

Latest From Medicure Inc.

Neurocrine's US Label For Ingrezza Should Provide Edge Over Teva's Austedo In TD

A summertime battle is expected between Neurocrine and Teva once both companies get their tardive dyskinesia drugs on the US market, but Neurocrine's April 11 approval for Ingrezza without an FDA warning label is already giving the biotech an edge.

Approvals Business Strategies

Keeping Track: FDA Nixes Medicure’s Aggrastat For STEMI, Approves Insys’ Syndros

The latest drug development news and highlights from our FDA Performance Tracker

Approvals BioPharmaceutical

Keeping Track: Allergan Antipsychotic Vraylar Approved; First-Line Imbruvica Claim Submitted

The latest drug development news and highlights from our FDA Performance Tracker.

BioPharmaceutical Clinical Trials

Pressure off Teva's CNS hopes as tardive dyskinesia drug succeeds

Teva's investigational drug SD-809 (deutetrabenazine) has hit its endpoint in moderate to severe tardive dyskinesia patients in a pivotal Phase II/III trial, top-line results show. The drug, which Teva acquired when it bought Auspex Pharmaceuticals earlier this year, is one of the leading candidates in this neurological disease, for which there are currently no approved treatments in the US.

Neurology Clinical Trials
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Renal System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Bioconnect Systems Inc.
  • Senior Management
  • Adam Dakin, CEO
    Mike Dugery, VP, R&D & Bus. Dev.
  • Contact Info
  • Bioconnect Systems Inc.
    Phone: (215) 646-6830
    124 S. Maple St.
    Ste. 220
    Ambler, PA 19002
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register